Latest From Lupin Ltd.
Indian pharmaceutical companies will soon be asked to seek a no objection certificate for the export of 12 APIs and their formulations, as the country deals with Chinese raw material supply disruptions on the back of the coronavirus crisis. However, the move is not expected to impact the export quantum for now.
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
After lower growth in its India business and impaired operations at five manufacturing units hit by US FDA action impacted Lupin's third-quarter revenues, one-offs sent its net profit crashing. While deferring reinspection timelines for its Goa and Somerset plants, the company remains confident of adding at least 15 products to its US portfolio in FY21.
- Controlled Release
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Lupin Laboratories
- Parent & Subsidiaries
- Lupin Ltd.
- Senior Management
Vinita Gupta, CEO
Ramesh Swaminathan , CFO
- Contact Info
Phone: (91) 22 6640 2222
B/4 Laxmi Towers, Bandra Kurla Complex
Mumbai, 400 051
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.